5 results match your criteria: "Vall Hebron's Research Institute and Universitat Autònoma de Barcelona[Affiliation]"
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
N Engl J Med
May 2018
From the Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, Rome (F.D.B.), Clinica Pediatrica e Reumatologia, Unità Operativa Semplice Dipartimentale di Malattie Autoinfiammatorie e Immunodeficienze, IRCCS, Istituto G. Gaslini, Genoa (M.G.), the Pediatric Clinic, University of Brescia and Spedali Civili, Brescia (M.C.), and the Amyloidosis Research and Treatment Center, Biotechnology Research Laboratories, Fondazione IRCCS Policlinico San Matteo, Pavia (L.O.) - all in Italy; the Division of Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona (J.A.), and the Internal Medicine Department, Autoimmune and Systemic Diseases Unit, Hospital Vall d'Hebron (S.B.-R.), Barcelona, and the Pediatric Rheumatology Unit, Hospital Universitario y Politécnico La Fe, Valencia (I.C.P.) - all in Spain; the Rheumatology Unit, Hadassah-Hebrew University Hospital (E.B.-C.), and the Pediatric Rheumatology Unit, Shaare Zedek Medical Center (P.J.H.), Jerusalem, and Heller Institute of Medical Research and Medicine Faculty, Sheba Medical Center, Tel-Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv (A.L.) - all in Israel; the Division of Pediatrics, University Medical Center Utrecht, Utrecht (J.F.), and the Radboud Expertise Center for Immunodeficiency and Autoinflammation, Department of Internal Medicine, Radboud University Medical Center, Nijmegen (A. Simon) - both in the Netherlands; the Departments of Pediatrics and Medicine, University of California at San Diego and Rady Children's Hospital San Diego, San Diego (H.M.H.); the Department of Pediatric Rheumatology, Centre de Référence des Maladies Auto-inflammatoires et de l'Amylose Inflammatoire, Centre Hospitalier Universitaire (CHU) de Bicêtre, Assistance Publique-Hopitaux de Paris (APHP), Université de Paris Sud (I.K.-P.), and Paris-Descartes University, Imagine Institute, Unité d'Immuno-Hématologie et Rhumatologie Pédiatrique, Hôpital Necker-Enfants Malades, APHP (P.Q.), Paris; the National Amyloidosis Centre, University College London Division of Medicine, Royal Free Campus (H.J.L.), and University College London, Great Ormond Street Institute of Child Health, and Great Ormond Street Hospital for Children NHS Foundation Trust (P.B.), London; the Department of Pediatrics, Hacettepe University, Ankara (S.O.), and the Department of Pediatric Rheumatology, Cerrahpasa Medical School (O.K.), and Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology (A.G.), Istanbul University, Istanbul - all in Turkey; the Department of Pediatrics, Division of Pediatric Rheumatology, Cleveland Clinic, Cleveland (A.Z.); the Department of Infectious Diseases and General Internal Medicine, CHU Sart-Tilman, University of Liège, Liege (M.M.), and the Department of Infectious Diseases and Immunity, Jessa Hospital, University of Hasselt, Hasselt (J.V.H.) - both in Belgium; the Department of Clinical Immunology, Center for Pediatric Hematology, Oncology, and Immunology, Moscow (A. Shcherbina); Pediatric Rheumatology of Western Switzerland, University of Lausanne, Lausanne, (M.H.), and Novartis, Basel (K.L., A. Speziale, G.J.) - both in Switzerland; the Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan (R.H.); and the Department of Pediatrics, Semmelweis Egyetem, Budapest, Hungary (T.C.).
Background: Familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor receptor-associated periodic syndrome (TRAPS) are monogenic autoinflammatory diseases characterized by recurrent fever flares.
Methods: We randomly assigned patients with genetically confirmed colchicine-resistant familial Mediterranean fever, mevalonate kinase deficiency, or TRAPS at the time of a flare to receive 150 mg of canakinumab subcutaneously or placebo every 4 weeks. Patients who did not have a resolution of their flare received an add-on injection of 150 mg of canakinumab.
Arterial Stiffness Is Associated With Basal Ganglia Enlarged Perivascular Spaces and Cerebral Small Vessel Disease Load.
Stroke
May 2018
From the Neurovascular Laboratory, Vall Hebron's Research Institute, Barcelona, Spain (I.R.-L., J.J.-B., X.C., A.L.-R., J.M., P.D.).
Background And Purpose: We assessed whether the load of cerebral small vessel disease (cSVD) and its individual markers, including lacunes, white matter hyperintensities, microbleeds, and enlarged perivascular spaces (EPVS), are associated with arterial stiffness.
Methods: We evaluated cSVD markers in a cohort of 782 hypertensive individuals without history of stroke or dementia. The load of the disease was calculated using an ordinal scale ranging from 0 to 4 (1 point was given for each of the 4 markers examined).
Endovascular treatment improves cognition after stroke: A secondary analysis of REVASCAT trial.
Neurology
January 2017
From the Department of Neuroscience (E.L.-C., M.J., M.G., M.H.-P., C.C., A.D.), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain; Stroke Institute (T.G.J.), Department of Neurology, UPMC, Pittsburgh, PA; Statistics and Operations Research (E.C.), Barcelona-Tech; Bioclever (N.C.), Department of Statistics; Hospital de Bellvitge (P.C., B.L.), L'Hospitalet de Llobregat; Hospital Clínic i Provincial (A.R., L.L.); and Hospital Vall d'Hebron (S.B., M.M.), Barcelona, Spain.
Objective: To investigate the effect of endovascular treatment on cognitive function as a prespecified secondary analysis of the REVASCAT (Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours) trial.
Methods: REVASCAT randomized 206 patients with anterior circulation proximal arterial occlusion stroke to Solitaire thrombectomy or best medical treatment alone. Patients with established dementia were excluded from enrollment.
Dementia Rating Scale-2 normative data for middle-and older-aged Castilian speaking Spaniards.
Clin Neuropsychol
May 2017
a Neurovascular Research Laboratory , Vall Hebron's Research Institute and Universitat Autònoma de Barcelona, Barcelona , Spain.
Objectives: The Dementia Rating Scale-2 (DRS-2) is frequently used as a dementia screening tool in clinical and research settings in Spain. The present study describes DRS-2 Total and subscale scores in community-dwelling Spaniards, aged 50-71, and provides normative data for its use in Castilian Spanish-speaking individuals.
Methods: The sample consisted of 798 individuals who participated in an observational study on essential hypertension.
Prevalence and associated factors of silent brain infarcts in a Mediterranean cohort of hypertensives.
Hypertension
September 2014
From the Neurovascular Research Laboratory, Vall Hebron Research Institute (P.D., I.R.-L., A.L.-R., C.N., J.M.), Barcelona City Research Support Unit-IDIAP Jordi Gol (X.M., F.O.), Departament de Medicina (J.L.), and Departament d'Infermeria (J.M.M.), Universitat Autònoma de Barcelona, Bellaterra, Spain; Nephrology Service (J.L.T.) and Department of Neurology, Neurovascular Section (J.Á.-S, O.M., J.M.), Vall Hebron's University Hospital, Barcelona, Spain; Emergency Department, CUAP Horta, Barcelona, Spain (C.I.J.); Equip d'Atenció Primària Sant Roc, Institut Català de la Salut, Badalona, Spain (J.L.); Unitat de Suport a la Recerca Metropolitana Nord, IDIAP Jordi Gol, Sabadell, Spain (J.M.M.); and Neurorradiology, Clínica Dr Manchón, Barcelona, Spain (J.L.F.).
Silent brain infarcts (SBIs) are detected by neuroimaging in approximately 20% of elderly patients in population-based studies. Limited evidence is available for hypertensives at low cardiovascular risk countries. Investigating Silent Strokes in Hypertensives: a Magnetic Resonance Imaging Study (ISSYS) is aimed to assess the prevalence and risk factors of SBIs in a hypertensive Mediterranean population.
View Article and Find Full Text PDF